 |
Video: What is a Stock Split?
|
 |
Dyne Therapeutics is a muscle disease company focused on developing therapeutics for people living with genetically driven diseases. Co. is developing the following product candidates: DYNE-101, to address the genetic basis of myotonic dystrophy type 1 by targeting the toxic nuclear DMPK RNA that causes the disease; DYNE-251 for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44; and DYNE-301 to address the genetic basis of facioscapulohumeral dystrophy by reducing DUX4 expression in muscle tissue. According to our DYN split history records, Dyne Therapeutics has had 3 splits. | |
 |

Dyne Therapeutics (DYN) has 3 splits in our DYN split history database. The first split for DYN took place on August 22, 2000. This was a 2 for 1 split, meaning for each share of DYN owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. DYN's second split took place on February 01, 2000. This was a 69 for 100 reverse split, meaning for each 100 shares of DYN owned pre-split, the shareholder now owned 69 shares. For example, a 2000 share position pre-split, became a 1380 share position following the split. DYN's third split took place on May 25, 2010. This was a 1 for 5 reverse split, meaning for each 5 shares of DYN owned pre-split, the shareholder now owned 1 share. For example, a 1380 share position pre-split, became a 276 share position following the split.
When a company such as Dyne Therapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. When a company such as Dyne Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the DYN split history from start to finish, an original position size of 1000 shares would have turned into 276 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Dyne Therapeutics shares, starting with a $10,000 purchase of DYN, presented on a split-history-adjusted basis factoring in the complete DYN split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/17/2020 |
|
End date: |
06/02/2023 |
|
Start price/share: |
$23.90 |
|
End price/share: |
$13.43 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-43.81% |
|
Average Annual Total Return: |
-19.18% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,619.11 |
|
Years: |
2.71 |
|
|
 |
Date |
Ratio |
08/22/2000 | 2 for 1 | 02/01/2000 | 69 for 100 | 05/25/2010 | 1 for 5 |
|
 |